Major depression can be debilitating; it not only deteriorates the quality of life, but can also be fatal. Selective serotonin reuptake inhibitors (SSRIs) are used in the first-line for the management of major depressive disorder (MDD). Escitalopram – an SSRI, demonstrates a highly selective and dose-dependent inhibitory action on the serotonin transport. 

A recent review aimed to explore the potency of escitalopram, which is a clinically approved therapeutic for MDD and panic disorders.Data for this study were derived from comparative and clinical trial studies from various databases––that reviewed several pharmacological targets. 

The results underscored the clinical efficacy, safety, increased bioavailability, and stable formulation of escitalopram. Based on the available clinical evidence and pharmacoeconomic data, it was concluded that escitalopram is an effective first-line therapeutic modality for MDD patients.